<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502954</url>
  </required_header>
  <id_info>
    <org_study_id>ABY-039-001</org_study_id>
    <secondary_id>2017-002918-32</secondary_id>
    <nct_id>NCT03502954</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039</brief_title>
  <official_title>A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affibody</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Affibody</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-human study is to investigate the safety and tolerability of
      ABY-039 after single and multiple doses in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of (related) treatment emergent adverse events of single intravenous (IV) and subcutaneous (SC) infusions/injections, and multiple SC injections</measure>
    <time_frame>Baseline up-to 11 weeks post-dose</time_frame>
    <description>Determining the incidence, severity, and dose relationship of adverse events that are related to treatment with ABY-039</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ABY-039 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ABY-039 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ABY-039</intervention_name>
    <description>ABY-039</description>
    <arm_group_label>ABY-039 IV</arm_group_label>
    <arm_group_label>ABY-039 SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo IV</arm_group_label>
    <arm_group_label>Placebo SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female subjects between 18 to 55 years of age agreeing to use highly
             effective methods of contraception

          2. Body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive, with a weight of at
             least 50 kg

          3. Non-smoker

          4. Subjects in good health

          5. Subjects with total immunoglobulin G (IgG) &gt; 10 g/L at Screening

        Exclusion Criteria:

          1. Subjects who have donated blood in the 3 months prior to Screening, plasma in the 7
             days prior to Screening or platelets in the 6 weeks prior to Screening

          2. Subjects who have received systemic corticosteroid treatment within 3 months of first
             dosing

          3. Subjects who have a history of significant drug allergy (e.g., anaphylaxis) or any
             clinically significant allergic condition (excluding non-active hay fever), as
             determined by the investigator

          4. Subjects who are still participating in another clinical study or received last
             investigational medical product (IMP) dose in a clinical study within the following
             time period prior to dosing: 3 months or 5 half-lives, whichever is longer

          5. History of splenectomy, asthma (exception of resolved childhood asthma), or chronic
             obstructive pulmonary disease (COPD)

          6. Positive for hepatitis A, hepatitis B, hepatitis C virus or antibodies to HIV-1 and/or
             HIV-2 or a positive QuantiFERON Gold Plus test at Screening

          7. Subjects who have received a live vaccination within 3 months prior to Screening or
             plan to have a live vaccination within 3 months after the last dose of study drug

          8. Subject unable or unwilling to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muna Albayaty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muna Albayaty, MD</last_name>
    <phone>01895614592</phone>
    <email>Muna.Albayaty@parexel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PAREXEL Early Phase Unit</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muna Albayaty, Dr</last_name>
      <phone>01895614592</phone>
      <email>Albayaty@parexel.com</email>
    </contact>
    <contact_backup>
      <last_name>Pablo Forto Soto</last_name>
      <phone>01895614355</phone>
      <email>pablo.fortosoto@parexel.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

